HOME >> BIOLOGY >> NEWS
Hydroxyurea therapy improves survival in most severely affected sickle cell patients

Sickle cell anemia patients who took the drug hydroxyurea over a 9-year period experienced a 40 percent reduction in deaths, according to the first study to evaluate whether the treatment prolongs life, announced the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.

The study of 299 adult sickle cell patients with moderate to severe forms of the disease, found that improved survival was related to the benefits associated with hydroxyurea treatment an increase in fetal hemoglobin and reduced episodes of severe pain "crises" and chest syndrome, a pneumonia-like illness. The results were published in the April 2 issue of The Journal of the American Medical Association.

Previous research has shown the benefits of hydroxyurea in reducing the symptoms of the most severely affected sickle cell patients those who have 3 or more painful crises each year.

"The current study shows that hydroxyurea can improve the survival of the sickest patients. Now there is new hope for these patients, who typically die 10 to 15 years earlier than patients with milder cases," said NHLBI Director Claude Lenfant, M.D.

Patients in the new study were originally participants in the NHLBI's Multicenter Study of Hydroxyurea (MSH) in Sickle Cell Anemia. That clinical trial was designed to test whether hydroxyurea reduced symptoms of the disease compared to placebo in patients who had 3 or more crises per year. Patients were randomly assigned to hydroxyurea or placebo and the study was "double-blinded" indicating neither patients nor physicians knew who was taking the drug.

Over 2 1/ 2 years, the drug resulted in an almost 50 percent reduction in the number of painful crises and episodes of chest syndrome. Patients on hydroxyurea also required about 50 percent fewer transfusions and hospitalizations. These results, reported in 1995, were reviewed by the Food and Drug Administration (FDA) and hydroxyurea became the first FDA
'"/>

Contact: NHLBI Communications Office
301-496-4236
NIH/National Heart, Lung, and Blood Institute
1-Apr-2003


Page: 1 2 3

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
3. Columbia research to examine gene influence on severity of peridontal disease, therapy response
4. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
5. The search for a kinder, gentler chemotherapy
6. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
7. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
8. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
9. Jefferson Lab detector technology aids development of cystic fibrosis therapy
10. Stroking up cellular therapy
11. Smart gene therapy protects against damage from heart attack

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2018)... ... , ... With increasing safety requirements, and time and financial pressure, the development ... To be successful in such a competitive environment, it is more important than ever ... needed to develop a new drug or to execute fundamental research. , In ...
(Date:8/15/2018)... ... August 15, 2018 , ... The Florida Chiropractic Association’s National Meeting ... Doctors from around the U.S. will gain firsthand insights into the new laser’s ... completed another successful clinical trial that has resulted in the granting of an ...
(Date:8/14/2018)... ... August 13, 2018 , ... Castle Dental® has partnered ... office on South Lamar Blvd. to provide free dental services for underinsured, low-income ... include x-rays and exams, fillings , extractions , cleanings ...
Breaking Biology News(10 mins):
(Date:7/31/2018)... , ... July 31, 2018 , ... ... for 65 years, announces the launch of their new website. The new website ... experience throughout the site. Mahoney partnered with Proceed Innovative to build a website ...
(Date:7/25/2018)... ... July 25, 2018 , ... ... energy treated proprietary nutraceutical to combat inflammation and autoimmune disorders. , The ... function response. The following data was reported:, Over ...
(Date:7/25/2018)... ... July 25, 2018 , ... John McDonald, CEO ... board of the Indiana India Business Council (IIBC), an advocacy group to strengthen ... current board of directors, McDonald joins an impressive roster of local and national ...
(Date:7/24/2018)... ... July 24, 2018 , ... On August 6, ... SmartTRAK platform. Not just a pretty face, SmartTRAK 3.0’s latest improvements were ... SmartTRAK is the world’s first online and real-time data portal that specializes in ...
Breaking Biology Technology:
Cached News: